Guy’s cancer cohort – real world evidence for cancer pathways

Moss, Charlotte; Haire, Anna; Cahill, Fidelma; Enting, Deborah; Hughes, Simon; Smith, Daniel; Sawyer, Elinor J.; Davies, Andrew; Zylstra, Janine; Haire, Kate; Rigg, Anne; Hemelrijck, Mieke Van

doi:10.1186/s12885-020-6667-0

Cited by 14 publications

(14 citation statements)

References 23 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Guy's Cancer Cohort, a research ethics committee approved research database (Reference number: 18/NW/0297) of all routinely collected clinical data of cancer patients at Guy's and St Thomas' NHS Foundation Trust (GSTT), forms the basis of this observational study (25). The database contains routinely collected prospective and retrospective demographic/clinical data on all cancer patients treated at Guy's Cancer Center.…”

Section: Study Populationmentioning

confidence: 99%

Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London

et al. 2020

View full text Add to dashboard Cite

Background: There is insufficient evidence to support clinical decision-making for cancer patients diagnosed with COVID-19 due to the lack of large studies. Methods: We used data from a single large UK Cancer Center to assess the demographic/clinical characteristics of 156 cancer patients with a confirmed COVID-19 diagnosis between 29 February and 12 May 2020. Logistic/Cox proportional hazards models were used to identify which demographic and/or clinical characteristics were associated with COVID-19 severity/death. Results: 128 (82%) presented with mild/moderate COVID-19 and 28 (18%) with a severe case of the disease. An initial cancer diagnosis >24 months before COVID-19 [OR: 1.74 (95% CI: 0.71-4.26)], presenting with fever [6.21 (1.76-21.99)], dyspnea [2.60 (1.00-6.76)], gastro-intestinal symptoms [7.38 (2.71-20.16)], or higher levels of C-reactive protein [9.43 (0.73-121.12)] were linked with greater COVID-19 severity. During a median follow-up of 37 days, 34 patients had died of COVID-19 (22%). Being of Asian ethnicity [3.73 (1.28-10.91)], receiving palliative treatment [5.74 (1.15-28.79)], having an initial cancer diagnosis >24 months before [2.14 (1.04-4.44)], dyspnea [4.94 (1.99-12.25)], and increased CRP levels [10.35 (1.05-52.21)] were positively associated with COVID-19 death. An inverse association was observed with increased levels of albumin [0.04 (0.01-0.04)]. Conclusions: A longer-established diagnosis of cancer was associated with increased severity of infection as well as COVID-19 death, possibly reflecting the effects a more advanced malignant disease has on this infection. Asian ethnicity and palliative treatment were also associated with COVID-19 death in cancer patients.

show abstract

Section: Study Populationmentioning

confidence: 99%

Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London

et al. 2020

View full text Add to dashboard Cite

show abstract

“…All data was collected and analyzed as part of Guy's Cancer Cohort (Ethics Reference number: 18/ NW/0297). 5 2,647 patients attended for outpatient, chemotherapy, or radiotherapy appointments from across South East London (and England) (Figure 1). Of these, 654 were swabbed for COVID-19 (25%).…”

mentioning

confidence: 99%

One Piece of the Jigsaw for the Cancer Recovery Strategy: Prevalence of COVID-19 in Patients With Cancer

et al. 2020

View full text Add to dashboard Cite

COVID-19 has forced governments to make drastic changes to healthcare systems. To start making informed decisions about cancer care, we need to understand the scale of COVID-19 infection. Therefore, we introduced swab testing for patients visiting Guy’s Cancer Centre. Our Centre is one of the largest UK Cancer Centers at the epicenter of the UK COVID-19 epidemic. The first COVID-19 positive cancer patient was reported on 29 February 2020. We analyzed data from 7-15 May 2020 for COVID-19 tests in our cancer patients. 2,647 patients attended for outpatient, chemotherapy, or radiotherapy appointments. 654 were swabbed for COVID-19 (25%). Of those tested, 9 were positive for COVID-19 (1.38%) of which 7 were asymptomatic. Cancer service providers will need to understand their local cancer population prevalence. The absolute priority is that cancer patients have the confidence to attend hospitals and be reassured that they will be treated in a COVID-19 managed environment.

show abstract

“…Here, we analyzed data from 1st March to 30th June 2020 for COVID-19 test results in all cancer patients at our center. All data was collected and analyzed as part of Guy's Cancer Cohort (Ethics Reference number: 18/NW/0297) [9], a research ethics committee-approved research database of all routinely collected clinical data of cancer patients diagnosed or treated at Guy's and St Thomas' (GSTT) NHS Foundation Trust. Over 83% of patients filled out a symptom assessment form, of which 82% were asymptomatic.…”

Section: Methodsmentioning

confidence: 99%

COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients

Russell

Moss

Palmer

et al. 2021

Cancers

View full text Add to dashboard Cite

Very few studies investigating COVID-19 in cancer patients have included cancer patients as controls. We aimed to identify factors associated with the risk of testing positive for SARS CoV2 infection in a cohort of cancer patients. We analyzed data from all cancer patients swabbed for COVID-19 between 1st March and 31st July 2020 at Guy’s Cancer Centre. We conducted logistic regression analyses to identify which factors were associated with a positive COVID-19 test. Results: Of the 2152 patients tested for COVID-19, 190 (9%) tested positive. Male sex, black ethnicity, and hematological cancer type were positively associated with risk of COVID-19 (OR = 1.85, 95%CI:1.37–2.51; OR = 1.93, 95%CI:1.31–2.84; OR = 2.29, 95%CI:1.45–3.62, respectively) as compared to females, white ethnicity, or solid cancer type, respectively. Male, Asian ethnicity, and hematological cancer type were associated with an increased risk of severe COVID-19 (OR = 3.12, 95%CI:1.58–6.14; OR = 2.97, 95%CI:1.00–8.93; OR = 2.43, 95%CI:1.00–5.90, respectively). This study is one of the first to compare the risk of COVID-19 incidence and severity in cancer patients when including cancer patients as controls. Results from this study have echoed those of previous reports, that patients who are male, of black or Asian ethnicity, or with a hematological malignancy are at an increased risk of COVID-19.

show abstract

Guy’s cancer cohort – real world evidence for cancer pathways

Cited by 14 publications

References 23 publications

Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London

Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London

One Piece of the Jigsaw for the Cancer Recovery Strategy: Prevalence of COVID-19 in Patients With Cancer

COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients

Contact Info

Product

Resources

About